The startup recently raised a $106 million Series C extension round led by Insight Partners and Battery Ventures. This comes two years after a $223 million Series C round led by T. Rowe Price and Fidelity. While awaiting full FDA approval for general heart screening, Cleerly's algorithms have been cleared for diagnosing symptomatic patients. The company's software has been commercially available for the last four years, and has seen a compounded annual growth of over 100%.
Key takeaways:
- Cleerly, a cardiovascular imaging startup, uses AI software to analyze CT scans of the heart to identify early stage coronary artery disease, similar to how mammograms and colonoscopies detect breast and colon cancer.
- The company is currently running a large clinical trial to prove that its screen can catch heart conditions in people without disease symptoms more accurately than other routine non-invasive methods.
- Cleerly recently raised a $106 million Series C extension round led by Insight Partners and joined by Battery Ventures, following a $223 million Series C led by T. Rowe Price and Fidelity two years ago.
- While awaiting full FDA approval for general heart screening, Cleerly's algorithms have already been cleared for diagnosing symptomatic patients, and Medicare has approved coverage for its plaque analysis test.